Thrombolytic and fibrinogenolytic properties of bioconjugate streptokinase-polyamidoamine dendrimers in vitro

Мухаметова, Л.И.; Айсина, Р.Б.; Zakharyan, E. M.; Караханов, Э. А.; Gershkovich, K.B.; Varfolomeyev, S.D.

doi:10.1016/j.thromres.2017.04.008

Cited by 12 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fibrinolysis rates were nearly identical for the PA dendrimer and free SK. Other studies using SK in dendrimers report slightly enhanced lysis rates and reduced fibrinogen degradation …”

Section: Macromolecule Modification Of Plasminogen Activatorsmentioning

confidence: 88%

“…Other studies using SK in dendrimers report slightly enhanced lysis rates 44 and reduced fibrinogen degradation. 45 Other macromolecule modifications focus on coupling PA to macromolecules that target activated platelets, activated endothelial cells, or fibrin. 28 Bode et al conjugated uPA to a monoclonal antibody to the integrin α IIb β 3 on platelets.…”

Section: Macromolecule Modific Ation Of Pl a S Minog En Ac Tivator Smentioning

confidence: 99%

See 1 more Smart Citation

Engineered microparticles and nanoparticles for fibrinolysis

Disharoon

Marr

Neeves

2019

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Fibrinolytic agents including plasmin and plasminogen activators improve outcomes in acute ischemic stroke and thrombosis by recanalizing occluded vessels. In the decades since their introduction into clinical practice, several limitations of have been identified in terms of both efficacy and bleeding risk associated with these agents. Engineered nanoparticles and microparticles address some of these limitations by improving circulation time, reducing inhibition and degradation in circulation, accelerating recanalization, improving targeting to thrombotic occlusions, and reducing off‐target effects; however, many particle‐based approaches have only been used in preclinical studies to date. This review covers four advances in coupling fibrinolytic agents with engineered particles: (a) modifications of plasminogen activators with macromolecules, (b) encapsulation of plasminogen activators and plasmin in polymer and liposomal particles, (c) triggered release of encapsulated fibrinolytic agents and mechanical disruption of clots with ultrasound, and (d) enhancing targeting with magnetic particles and magnetic fields. Technical challenges for the translation of these approaches to the clinic are discussed.

show abstract

“…Fibrinolysis rates were nearly identical for the PA dendrimer and free SK. Other studies using SK in dendrimers report slightly enhanced lysis rates and reduced fibrinogen degradation …”

Section: Macromolecule Modification Of Plasminogen Activatorsmentioning

confidence: 88%

Section: Macromolecule Modific Ation Of Pl a S Minog En Ac Tivator Smentioning

confidence: 99%

Engineered microparticles and nanoparticles for fibrinolysis

Disharoon

Marr

Neeves

2019

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…Particulate nanocarriers offer many advantages over direct conjugates for drug delivery including, but not limited to, drug stabilization, higher drug loading capability, controlled payload release, and potential for surface functionalization without interference with therapeutic activity of loaded drug. Physical encapsulation and surface immobilization of PAs have been investigated using different nanocarriers such as polymeric nanoparticles, [ 25,26 ] liposomes, [ 10,11,14,27–29 ] microbubbles (MB), [ 30,31 ] and dendrimers, [ 32,33 ] to control their biodistribution and stabilize them against rapid clearance and possible inactivating enzymes. Surface modification (such as PEGylation) of nanocarriers prolongs circulation lifetimes, resulting in enhanced fibrinolytic activity, especially when conjugated to targeting antibody fragments.…”

Section: Plasminogen Activator Nanodelivery Systemsmentioning

confidence: 99%

Smart Delivery of Plasminogen Activators for Efficient Thrombolysis; Recent Trends and Future Perspectives

Refaat

Rosal

Palasubramaniam

et al. 2021

Advanced Therapeutics

View full text Add to dashboard Cite

Fibrinolytic drugs have been successfully used to manage acute thrombotic and thromboembolic conditions. However, their narrow administration time window, rapid clearance, and possible inactivation limit their efficient and wider application. Most importantly, they present a substantial risk of fatal bleeding complications, which are a major cause of mortality and morbidity. Improving the therapeutic outcomes of pharmacological thrombolysis, including alleviating associated side effects, is an urgent challenge. In this context, nano‐drug delivery systems have attracted major interest. State‐of‐the‐art nanodelivery systems have achieved reduced immunogenicity and a significant prolongation of the biological half‐life of drugs, the latter allowing their application as boli instead of infusions. Recent research focuses on theranostic systems capable of image‐guided thrombolysis, clot targeting strategies, and stimuli‐responsive systems. The latter are designed so that an external or internal stimulus triggers the drug release, offering unique spatiotemporal control over the treatment and potentially minimizing side effects. In this review, the authors discuss the different nanodelivery platforms and focus on stimuli‐responsive systems, highlighting their therapeutic advantages and the challenges for their clinical translation.

show abstract

“…Cardio-protectant [125] Thrombosis [126] Atherosclerosis [127] Nanocoating Implants biocompatibility [128] Dendrimers Cardio-protectant [129] Thrombosis [130] Atherosclerosis [131] Vasodilation [132] Liposomes Cardio-protectant [133] Thrombosis [134] Atherosclerosis [135] Vasodilation [136] SLNs of RES have been utilised orally, augmenting drug plasma concentrations, and prolonging the duration of circulation. In the treatment of cardiovascular diseases, these characteristics are of great importance in order to achieve greater therapeutic outcomes.…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)

Houacine

Khan

Yousaf

2021

CPD

View full text Add to dashboard Cite

: With a 2030 projection of 23.6 million deaths per year the prevalence and severity of cardiovascular disease is at an astounding high. Thus, a definitive need for the identification of novel compounds with potential to prevent or treat the disease and associated states. Moreover, there is also an ever-increasing need for drug delivery systems (DDS) that cope with poor and ranging physiochemical properties of therapeutic compounds to achieve clinical effect. The usage of resveratrol (RES) is a growing area of interest with innumerate pieces of research evidencing the drug’s efficacy. This drug is however marred, its notably poor physiochemical properties (namely poor water solubility) limits its use for oral drug delivery. RES analogues however, potentially possess superior physiochemical characteristics offering a remedy for the aforementioned drawback. However, particulate based DDS are equally able to offer property amelioration and targeting. This review offers an extensive examination into the role of RES as a potential cardio protective agent. The prevalence and suitability of associated analogues and the role of nanotechnology in overcoming physicochemical boundaries, particularly through the development of nanoparticulate formulations, will be discussed in detail.

show abstract

Thrombolytic and fibrinogenolytic properties of bioconjugate streptokinase-polyamidoamine dendrimers in vitro

Cited by 12 publications

References 9 publications

Engineered microparticles and nanoparticles for fibrinolysis

Engineered microparticles and nanoparticles for fibrinolysis

Smart Delivery of Plasminogen Activators for Efficient Thrombolysis; Recent Trends and Future Perspectives

Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)

Contact Info

Product

Resources

About